Previous 10 | Next 10 |
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.22% on the day to $13.25. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapie...
2023-11-28 11:52:30 ET Summary Today, we revisit Olema Pharmaceuticals, Inc. for the first time in two years. Olema is a clinical-stage biotech company focused on developing therapies for women's cancers. Their primary product candidate, palazestrant, has been granted FDA Fast Tra...
2023-11-27 13:27:19 ET More on Markets BMO Capital Markets sets base-case S&P 500 target of 5,100 for 2024 Rate cuts, S&P upside and oil prices among BofA's key themes for 2024 VanEck highlights mid-caps as a potential sweet spot for investors For fur...
2023-11-22 17:09:08 ET Gainers: Aurora Innovation ( AUR ) +2% . Innodata ( INOD ) +2% . The Vita Coco Company ( COCO ) +2% . Immunovant ( IMVT ) +2% . The RealReal ( REAL ) +2% . Losers: BioCryst Pharmaceuticals ( ...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.22% on the day to $13.25. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapie...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.22% on the day to $13.25. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapie...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.22% on the day to $13.25. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapie...
Olema Pharmaceuticals Inc. (OLMA) is expected to report $-0.51 for Q3 2023
2023-11-07 18:05:15 ET Olema Pharmaceuticals press release ( NASDAQ: OLMA ): Q3 GAAP EPS of -$0.48. Cash, cash equivalents and marketable securities position of $276.9 million as of September 30, 2023. For further details see: Olema Pharmaceuticals GAAP E...
OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarter New clinical data for palazestrant (OP-1250) in combination with CDK4/6 inhibitors to be presented at the 2023 San Antonio Breast...
News, Short Squeeze, Breakout and More Instantly...
Olema Pharmaceuticals Inc. Company Name:
OLMA Stock Symbol:
NASDAQ Market:
Olema Pharmaceuticals Inc. Website:
2024-06-13 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 15:30:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for OLMA on June 4, 2024 02:10PM ET. The previous analyst recommendation was Outperform. OLMA was trading at $14.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is one of today's top gainers. The company's shares have moved 17.73% on the day to $13.84. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's ...